Agilent Technologies Inc. (NYSE: A) and MRM Proteomics Inc. today announced the launch of MRM Proteomics’ PeptiQuant MRM Assay Kits for quality control in quantitative plasma proteomic analyses based on multiple-reaction monitoring.
- The PeptiQuant LC-MS Platform Performance Kit tests the effectiveness of the LC-MS platform.
- The PeptiQuant Workflow Performance Kit evaluates the performance of an entire LC-MRM-MS analytical workflow in human plasma from denaturation through digestion to detection.
About MRM ProteomicsMRM Proteomics Inc. is a leader in providing advanced protein quantitation, analytical proteomic services and reagents to the pharmaceutical, biotechnology and diagnostics industries in key areas such as biomarker discovery/validation and clinical diagnostics development. Information about MRM Proteomics is available at www.mrmproteomics.com. About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company’s 20,500 employees serve customers in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal 2012. Information about Agilent is available at www.agilent.com. NOTE TO EDITORS: Further technology, corporate citizenship, and executive news is available on the Agilent news site at www.agilent.com/go/news.